Committee for Orphan Medicinal Products (COMP), European Medicines Agency (EMA), London, UK; Autonomous University, Barcelona, Spain.
Outcomes'10, Castellon, Spain.
Health Policy. 2018 Jun;122(6):590-598. doi: 10.1016/j.healthpol.2018.03.002. Epub 2018 Mar 15.
To reach a consensus amongst experts on the most feasible actions to be undertaken to facilitate patient access to specialised care and orphan drugs (OD) in the public health sector in Spain.
Two Delphi rounds were completed. The questionnaire was based on a literature review and 2 focus groups. Agreement was sought on the desire (D) and prognosis (P) for the implementation within the next 5 years, on a 5-point Likert scale. Consensus was reached when ≥75% participants chose agreement (1-2) or disagreement options (4-5).
82 experts on rare disease (RD) participated. Agreement on the D and P was reached in 66.07% statements: OD pricing review [absence of clinical effectiveness (D:85.37%; P:85.90%), target population increase (D:79.27%; P:91.03%)]; reference team definition of referral protocols and clinical practice guidelines (D: 97.56%; P: 89.74%); and a unified, usable, etiology-based registry (D:97.56%; P:84.62%). D and P assessment diverged in 32.14% items: creation of a specific funding system for OD (D: 97.56%; P: 60.25%); and a network of medical teams to coordinate the care of RD patients (D: 99%; P: 62%).
The results have shown the need to promote dialogue between stakeholders, introduce European recommendation to national and regional Spanish policies and set up priorities and undertake actions to drive relevant changes in current medical practice in managing RD patients.
就如何在西班牙公共卫生部门为患者获得专科治疗和罕见病药物(OD)提供便利,在专家中达成最可行的行动共识。
完成了两轮 Delphi 研究。问卷基于文献回顾和 2 个焦点小组。采用 5 分李克特量表,对未来 5 年内实施的意愿(D)和预测(P)进行了评估。当≥75%的参与者选择同意(1-2)或不同意(4-5)选项时,即可达成共识。
共有 82 名罕见病专家参与。在 66.07%的陈述中达成了对 D 和 P 的共识:OD 定价审查[缺乏临床疗效(D:85.37%;P:85.90%)];目标人群增加(D:79.27%;P:91.03%)];参考小组制定转诊协议和临床实践指南(D:97.56%;P:89.74%);以及建立一个统一、可用、基于病因的登记系统(D:97.56%;P:84.62%)。在 32.14%的项目中,D 和 P 的评估存在分歧:为 OD 创建特定的资金系统(D:97.56%;P:60.25%);以及建立一个协调 RD 患者护理的医疗团队网络(D:99%;P:62%)。
结果表明,需要促进利益相关者之间的对话,将欧洲建议引入国家和地区西班牙政策,并确定优先事项并采取行动,推动当前管理 RD 患者医疗实践的相关变革。